Your Daily Sleep Science Briefing

FDA Accepts New Drug Application for Oral Obstructive Sleep Apnea Treatment

• The U.S. Food and Drug Administration (FDA) has accepted Apnimed's New Drug Application (NDA) for AD109, an investigational once-nightly oral combination therapy for obstructive sleep apnea (OSA), setting a target action date of February 28, 2027. This development follows positive results from the Phase 3 SynAIRgy trial, where AD109 reduced the apnea-hypopnea index (AHI) by an estimated 44.1% from baseline, signaling a potential shift towards more personalized, mechanism-directed OSA treatment beyond traditional continuous positive airway pressure (CPAP) therapy.

  Neurologylive

• New research indicates a significant link between frequent daytime napping and an elevated risk of dementia in older adults. A 10-year study tracking nearly 1,000 Medicare beneficiaries found that those who napped most days or daily had a 48% higher risk of developing dementia, independent of nighttime sleep patterns. Surprisingly, even unintentional naps or those lasting 30 minutes or less were associated with a 39% and 40% increased risk, respectively, suggesting that daytime sleep patterns could be early indicators of neurodegeneration.

  Neurosciencenews

• Alkermes plc is set to present new data on its sleep medicine portfolio at the European Sleep Research Society's (ESRS) 28th Congress, Sleep Europe 2026, taking place from October 20-23, 2026. The presentations will include detailed positive results from the REVITALYZ Phase 3 study evaluating LUMRYZ® (sodium oxybate) for adults with idiopathic hypersomnia, a chronic neurological disorder with limited treatment options, and initial long-term data on alixorexton for narcolepsy type 1 and 2.

  Businesswire